India, Oct. 8 -- Glaukos Corporation (GKOS) has entered into an exclusive licensing agreement with RevOpsis to develop and commercialize RO-104, a biologic being developed for several retinal diseases, including neovascular age-related macular degeneration (nMAD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO).
Retinal vascular diseases are among the leading causes of vision loss and are commonly treated with drugs that target proteins involved in abnormal blood vessel growth and leakage in the eye.
RO-104 is designed as a first-in-class tri-specific biologic that simultaneously targets three pathways linked to retinal disease progression: VEGF-A, VEGF-C, and Ang-2. According to the companies, th...